SEPN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

37.480

Open

34.710

VWAP

36.29

Vol

588.61K

Mkt Cap

1.51B

Low

34.710

Amount

21.36M

EV/EBITDA(TTM)

Total Shares

45.08M

1.19B

EV/OCF(TTM)

10.98

P/S(TTM)

21.07

Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

Events Timeline

(ET)

2026-05-11

16:10:00

Septerna Reports Q1 Revenue of $26.52M, Exceeding Expectations

2026-04-13 (ET)

2026-04-13

08:10:00

Septerna Doses First Participants in SEP-479 Clinical Trial

News

5.0

07-05NASDAQ.COM

Septerna Executive Sells Significant Stock Holdings

5.0

07-05Fool

Septerna Executive's Stock Sale Raises Concerns

5.0

07-05Yahoo Finance

Septerna Executive Sells Nearly 12,000 Shares: Implications for Investors

5.0

06-30Fool

Septerna Executive Sells Shares, Reduces Holdings by 13.46%

5.0

06-30NASDAQ.COM

Septerna Executive Sells Shares to Supplement Income

6.0

06-11CNBC

Latest Wall Street Ratings Overview

8 Analyst Rating

Wall Street analysts forecast SEPN stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

33.14

High

43.00

Current: 0.000

Low

25.00

Averages

33.14

High

43.00

Truist

Srikripa Devarakonda

Buy

maintain

$35 -> $43

AI Analysis

2026-07-01

Reason

Truist

Srikripa Devarakonda

Price Target

$35 -> $43

AI Analysis

2026-07-01

maintain

Buy

Reason

Truist analyst Srikripa Devarakonda raised the firm's price target on Septerna to $43 from $35 and keeps a Buy rating on the shares. Investor focus is shifting toward the hypoparathyroidism program ahead of a Phase 1 HV readout expected in late 2026 to early 2027, with increased probability of success assigned to HP based on TAM and early data, while the MRGPRX2 program is now ascribed no value pending further clarity after a competitor miss in CSU, and an additional $250M peak platform value has been added to reflect broader pipeline optionality, the analyst tells investors in a research note.

Guggenheim

Seamus Fernandez

Buy

downgrade

$52 -> $45

2026-07-01

Reason

Guggenheim

Seamus Fernandez

Price Target

$52 -> $45

2026-07-01

downgrade

Buy

Reason

Guggenheim analyst Seamus Fernandez lowered the firm's price target on Septerna (SEPN) to $45 from $52 and keeps a Buy rating on the shares after Evommune (EVMN) announced top-line results for their Phase 2b study of MRGPRX2 inhibitor, EVO756. The study did not meet the primary endpoint and Evommune has discontinued efforts in chronic spontaneous urticaria, notes the analyst, who believes Septerna's decision to wait on the Phase 2b initiation can enable capital-efficient exploration of SEP-631 in a smaller, signal-finding batch study.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SEPN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Septerna Inc (SEPN.O) is 107.53, compared to its 5-year average forward P/E of 18.72. For a more detailed relative valuation and DCF analysis to assess Septerna Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

18.72

Current PE

107.53

Overvalued PE

86.56

Undervalued PE

-49.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.01

Current EV/EBITDA

-47.26

Overvalued EV/EBITDA

5.66

Undervalued EV/EBITDA

-21.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

101.22

Current PS

23.27

Overvalued PS

357.49

Undervalued PS

-155.05

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

recomend a stock in the biotech field

Intellectia · 46 candidates

Industry: Biotechnology & Medical ResearchQuarter Revenue Yoy Growth: >= 0.0%Analyst Consensus: Strong Buy, Moderate BuyMoving Average Relationship: PriceAboveMA20, PriceCrossAboveMA20

Ticker

Name

Market Cap$

DTIL

Precision BioSciences Inc

215.19M

SEPN

Septerna Inc

1.12B

CGEN

Compugen Ltd

269.48M

CGON

CG Oncology Inc

6.53B

LXRX

Lexicon Pharmaceuticals Inc

1.08B

CYTK

Cytokinetics Inc

10.48B

stocks with 500 percent upside by 2027

Intellectia · 88 candidates

Quarter Revenue Yoy Growth: >= 0.0%Analyst Consensus: Strong Buy, Moderate BuyQuarter Eps Yoy Growth: >= 0.0%Target Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Is Optionable: True

Ticker

Name

Market Cap$

DTIL

Precision BioSciences Inc

211.58M

OBIO

Orchestra Biomed Holdings Inc

243.12M

SEPN

Septerna Inc

1.12B

CGEN

Compugen Ltd

267.59M

LXRX

Lexicon Pharmaceuticals Inc

1.07B

VRCA

Verrica Pharmaceuticals Inc

122.83M

which bio stocks is declining

Intellectia · 12 candidates

Market Cap: >= 1000.00MSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical ResearchVolume: >= 500,000Price Change Pct: <= $-2.00Moving Average Relationship: PriceBelowMA20

Ticker

Name

Market Cap$

TEM

Tempus AI Inc

7.70B

IBRX

Immunitybio Inc

7.52B

PTGX

Protagonist Therapeutics Inc

6.31B

ADPT

Adaptive Biotechnologies Corp

1.97B

TYRA

Tyra Biosciences Inc

1.90B

GRAL

Grail Inc

1.87B

best short term day trading stock

Intellectia · 3787 candidates

Price: $1.00 - $200.00List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 100,000

Ticker

Name

Market Cap$

ZNTL

Zentalis Pharmaceuticals Inc

210.44M

LAMR

Lamar Advertising Co

13.37B

REI

Ring Energy Inc

203.08M

SSTK

Shutterstock Inc

674.53M

AHCO

Adapthealth Corp

1.42B

CRH

CRH PLC

80.90B

Whales Holding SEPN

Driehaus Capital Management LLC

Avoro Capital Advisors LLC

RA Capital Management, L.P.

ADAR1 Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Septerna Inc (SEPN) stock price today?

The current price of SEPN is 36.68 USD — it has increased 9.59

What is Septerna Inc (SEPN)'s business?

What is the price predicton of SEPN Stock?

Wall Street analysts forecast SEPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEPN is33.14 USD with a low forecast of 25.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.